Intrathecal pump

CENTER FOR PAIN MANAGEMENT WELCOMES DR. JOSHUA WELLINGTON, MD.

Retrieved on: 
Friday, September 1, 2023
Spaulding Rehabilitation Hospital, Boston Children's Hospital, Intrathecal pump, Piriformis syndrome, Beth Israel Deaconess Medical Center, Neck pain, Arthralgia, Interventional pain management, Arthritis, Medical college, Therapy, Twilight anesthesia, ITP, Cancer, North American Neuromodulation Society, American Academy, CRPS, Medicine, MS, Harvard Medical School, Public key certificate, Back pain, Rehabilitation, Medical director, Patient, Physician, Practitioner, Physical medicine and rehabilitation, Fibromyalgia, Hospital, Health, NANS, Chronic pain, Headache, Society, Targeted drug delivery, Injury, Nursing, Dentistry, Pain management, MD

INDIANAPOLIS, Sept. 1, 2023 /PRNewswire/ -- Center for Pain Management, together with American Pain Consortium, a leading network of interventional pain practices, is pleased to announce that Joshua Wellington, MD, MS, has joined their practice and will be seeing patients starting September 5, 2023.

Key Points: 
  • INDIANAPOLIS, Sept. 1, 2023 /PRNewswire/ -- Center for Pain Management, together with American Pain Consortium, a leading network of interventional pain practices, is pleased to announce that Joshua Wellington, MD, MS, has joined their practice and will be seeing patients starting September 5, 2023.
  • He will be joining Center for Pain Management to lead the Targeted Drug Delivery program, which will expand patient access to quality care for Intrathecal Pump (ITP) implants.
  • Center for Pain Management, supported by American Pain Consortium, proudly serves Indiana with 7 clinics and 4 Ambulatory Surgery Centers statewide and has been treating a wide range of acute and chronic pain conditions since 1993.
  • The physicians specialize in back pain, neck pain, headache, and joint pain resulting from injuries, arthritis, cancer, fibromyalgia, failed back surgery, Complex Regional Pain Syndromes (CRPS), and other disorders.

Worldwide Intrathecal Pumps Industry to 2028 - Advantages of Intrathecal Pumps over Oral Medications are Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 21, 2021
Medical Devices, Health, Technology, Chronic pain, Cancer, Industry, Spasticity, Spinal cord, Medicine, Time, Intrathecal administration, Brain, Growth, COVID-19, CAGR, Awareness, Geography, Prevalence, Intrathecal pump, Medical device, Marketing

The increasing prevalence of cancer and other chronic conditions, advantages of intrathecal pumps over oral medications, and rise in geriatric population are among the major factors boosting the market growth.

Key Points: 
  • The increasing prevalence of cancer and other chronic conditions, advantages of intrathecal pumps over oral medications, and rise in geriatric population are among the major factors boosting the market growth.
  • However, the lack of awareness regarding advanced pain management techniques and high cost of intrathecal pumps hampers the market growth.
  • The intrathecal pumps market by type is segmented into constant rate pumps, and programmable pumps.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Intrathecal Pumps market.

Insights into the U.S. Neurological Devices Market to 2025 - Featuring Axonics, Boston Scientific & Cerenovus Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, March 27, 2020
Medical devices, Health, Medicine, Clinical medicine, Branches of biology, Pain, Neuromodulation, Neurophysiology, Neuropsychology, Neurotechnology, Neurosurgery, Intrathecal pump, Intrathecal administration

The "Neurological Devices Market Analysis, Size, Trends | US | 2019-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neurological Devices Market Analysis, Size, Trends | US | 2019-2025" report has been added to ResearchAndMarkets.com's offering.
  • The various segments of the neurological devices market, as well as the conditions they treat, are introduced below.
  • The U.S. market for neuromodulation, neurovascular and neurosurgical devices is collectively referred to as the U.S. neurological device market.
  • The full report suite on the U.S. market for neurological devices includes cerebrospinal fluid management, detachable coils, liquid embolics, neurovascular catheters, neurovascular guidewires, neurovascular stents, balloon occlusion devices, aneurysm clips, neurovascular thrombus management, neuromodulation devices, intrathecal pumps, stereotactic devices, neuroendoscopes and ultrasonic aspirators.

European Neurological Devices Market (2019 to 2025) - Analysis, Size & Trends - ResearchAndMarkets.com

Retrieved on: 
Friday, March 27, 2020
Surgery, Health, Medical devices, Pain, Branches of biology, Medicine, Neuroscience, Neurotechnology, Neuromodulation, Neurophysiology, Neuropsychology, Neurosurgery, Intrathecal pump

The "Neurological Devices Market Analysis, Size, Trends | Europe | 2019-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neurological Devices Market Analysis, Size, Trends | Europe | 2019-2025" report has been added to ResearchAndMarkets.com's offering.
  • The various segments of the neurological devices market, as well as the conditions they treat, are introduced below.
  • The European market for neuromodulation, neurovascular and neurosurgical devices is collectively referred to as the European neurological device market.
  • The full report suite on the European market for neurological devices includes cerebrospinal fluid management devices, detachable coils, liquid embolics, neurovascular guidewires, neurovascular catheters, neurovascular stents, aneurysm clips, intrasaccular stents, neurovascular thrombectomy devices, ultrasonic aspirators, neuromodulation devices, intrathecal pumps, stereotactic devices and transcranial magnetic simulators.

Flowonix Receives FDA Approval to Market Prometra® II Pump for use with Intrathecal Baclofen

Retrieved on: 
Wednesday, February 19, 2020
Medicine, Clinical medicine, Health, Intrathecal pump, Pain, Dosage forms, Intrathecal administration, Baclofen, Pump

MOUNT OLIVE, N.J., Feb. 19, 2020 /PRNewswire/ --Flowonix Medical, Inc. today announced United States Food and Drug Administration (FDA) approval to market the Prometra II Programmable Pump System for use with intrathecal baclofen.

Key Points: 
  • MOUNT OLIVE, N.J., Feb. 19, 2020 /PRNewswire/ --Flowonix Medical, Inc. today announced United States Food and Drug Administration (FDA) approval to market the Prometra II Programmable Pump System for use with intrathecal baclofen.
  • Flowonix introduced the Prometra II 40mL pump to the US market in November 2019, providing patients and clinicians a choice between 20 mL and 40 mL capacities when choosing an intrathecal pump delivery device.
  • The new indication expands significantly the market for the Prometra device by enabling its use in the treatment of spasticity.
  • Unlike the existing motor-driven pump, the Prometra II Pump utilizes a pressure-driven, valve-gated delivery mechanism to deliver boluses of medication into the intrathecal space.

Medtronic Launches Efficio™ Software to Help Clinicians Efficiently Manage Targeted Drug Delivery Therapy with SynchroMed™ II

Retrieved on: 
Thursday, January 23, 2020
Medicine, Health, Clinical medicine, Pain, Oncology, Intrathecal administration, Medtronic, Cancer pain, Spasticity, Neurological disorders, Intrathecal pump, Ocular neuropathic pain

DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the launch ofEfficio, a cloud-based data management software for use with the SynchroMed II intrathecal drug delivery system, that will allow clinicians to more efficiently manage their targeted drug delivery pump practices to treat patients with chronic pain, cancer pain and severe spasticity.

Key Points: 
  • DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the launch ofEfficio, a cloud-based data management software for use with the SynchroMed II intrathecal drug delivery system, that will allow clinicians to more efficiently manage their targeted drug delivery pump practices to treat patients with chronic pain, cancer pain and severe spasticity.
  • Efficio also helps me manage pump refill dates, pump replacements, and monitor trends in dosing and patient function.
  • Efficio marks another step in our journey to simplify targeted drug delivery therapy, said Charlie Covert, vice president and general manager of the Targeted Drug Delivery business, which is part of the Restorative Therapies Group at Medtronic.
  • The SynchroMed II intrathecal drug delivery system offers a safe, proven, and effective way to manage chronic pain, cancer pain and severe spasticity for appropriate patients.